Investigational New Drugs
Q2 Journal
Journal
Country
United States
Northern America
Subject Area and Category
Medicine
└
Oncology
Q2
└
Pharmacology
Q2
└
Pharmacology (medical)
Q2
Publisher
SJR 2025
0.816
Q2
SJR Score
H-Index
104
Citations / Doc (2yr)
2.76
Total Docs. (latest)
108
Total Citations (3yr)
875
Publication type
Journals
ISSN
01676997, 15730646
Coverage
1983-2026
Journal Rank
#6,711
Subject Categories
Oncology
Q2
Pharmacology
Q2
Pharmacology (medical)
Q2
Subject Areas
Aims & Scope
The development of new anticancer agents is one of the most rapidly changing aspects of cancer research.
Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents.
The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist.
Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.
Abstracting & Indexing
Scopus
Google Scholar
Web of Science
Medline
Embase
Detailed Metrics
| Total Docs. (latest) | 108 |
| Total Docs. (3 years) | 317 |
| Total Refs. | 4,796 |
| Total Citations (3 years) | 875 |
| Citable Docs. (3 years) | 309 |
| Citations / Doc. (2 years) | 2.76 |
| Ref. / Doc. | 44.41 |
| % Female | 40.1% |
Metrics Visualization
Latest year data vs 3-year cumulative figures
Publication & Citation Trend
Loading trend data from Crossref...
Top 10 Most Cited Articles
Loading articles...
Researcher Reviews
Write a ReviewNo reviews yet for this journal.
Be the first to share your experience!
Share Your Experience
Your review will be published after moderation. Email will not be displayed publicly.